Show Notes
In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly’s investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis.
Highlights:
Up to 28.7% weight loss (~71 lbs) over 68 weeks
75% reduction in knee pain and major improvements in physical function
Cardiometabolic benefits: lower triglycerides, non-HDL cholesterol, hsCRP, and blood pressure
We also cover
Common side effects and safety signals
Perceived excessive weight loss — and what this means for clinical practice in a new era of powerful medications
A reality check on Canadian availability (likely 3+ years away)
A strong warning about illegal online sales and the risks of buying unregulated products
A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.
More from The Obesity Doctor Podcast
In this episode, I’m joined by Dr. Ariel Dalfen, a psychiatrist and women’s mental health specialist, to explore the intersection of reproductive hormones, mental health, body image, eating disorders, and metabolic health.
Why does staying on track with weight loss often feel so much easier during the week, only to become more challenging once Friday afternoon rolls around?
What happens after you’ve lost the weight you wanted to lose?
In this episode, I sit down with Dr. Tasneem Sajwani, Medical Director of the Edmonton Weight Management Centre, for a behind-the-scenes look at the world of obesity medicine. We discuss how she found her passion for this field, the challenges and rewards of building a successful obesity medicine clinic, and the key elements that drive long-term patient success.
Significant weight loss can be life-changing for your health—but it can also lead to changes in facial volume, skin laxity, and the way we see ourselves in the mirror.